PXL01 program entering Phase III clinical trial

A biotech with global reach

Therapeutic peptides for bioactive wound care

Two first-in-category product candidates

New medical concept with extraordinary safety

Strategic partnerships in EU, Asia and USA

Innovative treatments for local administration

Press releases

November 12, 2019Promore Pharma is granted a patent for PXL01 in the US
November 12, 2019Promore Pharma publishes prospectus in connection with rights issue
October 22, 2019Report from the Extraordinary Shareholders’ Meeting of Promore Pharma AB held on 22 October 2019
October 21, 2019Promore Pharma engages ABG Sundal Collier as liquidity provider

More Press Releases

Second quarter 2019

Promore Pharma AB (publ) published its Interim report for the second quarter on 28 August 2019.

The next day, 29 August, the company will host a webcast telephone conference at 10.00 CET.

Read the report

Calendar

November 22, 2019Interim report January – September 2019
February 18, 2020Year-end report 2019

More Events

Promore Pharma is a biopharmaceutical company specialized in the development of therapeutic peptides for the bioactive wound care market. The company’s aim is to develop two first-in-category products for indications with very few efficacious prescription pharmaceuticals, addressing high unmet medical need.

Vision

The vision of Promore Pharma is to solve the global medical problems of scarring, adhesions and chronic wounds.

Market

Within the global wound care market Promore Pharma’s product candidates are intended for the bioactive wound care segment. The bioactive wound care segment constitutes the fastest growing segment within the overall wound care market with a projected annual growth rate from 2015-2020 of 14 percent and is expected to reach USD 7.3 billion in 2020.